Literature DB >> 20800383

Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.

Damien C Weber1, Safora Johanson, Nicolas Peguret, Luca Cozzi, Dag R Olsen.   

Abstract

PURPOSE: To assess the excess relative risk (ERR) of radiation-induced cancers (RIC) in female patients with Hodgkin lymphoma (HL) female patients treated with conformal (3DCRT), intensity modulated (IMRT), or volumetric modulated arc (RA) radiation therapy. METHODS AND MATERIALS: Plans for 10 early-stage HL female patients were computed for 3DCRT, IMRT, and RA with involved field RT (IFRT) and involvednode RT (INRT) radiation fields. Organs at risk dose--volume histograms were computed and inter-compared for IFRT vs. INRT and 3DCRT vs. IMRT/RA, respectively. The ERR for cancer induction in breasts, lungs, and thyroid was estimated using both linear and nonlinear models.
RESULTS: The mean estimated ERR for breast, lung, and thyroid were significantly lower (p < 0.01) with INRT than with IFRT planning, regardless of the radiation delivery technique used, assuming a linear dose-risk relationship. We found that using the nonlinear model, the mean ERR values were significantly (p < 0.01) increased with IMRT or RA compared to those with 3DCRT planning for the breast, lung, and thyroid, using an IFRT paradigm. After INRT planning, IMRT or RA increased the risk of RIC for lung and thyroid only.
CONCLUSIONS: In this comparative planning study, using a nonlinear dose--risk model, IMRT or RA increased the estimated risk of RIC for breast, lung, and thyroid for HL female patients. This study also suggests that INRT planning, compared to IFRT planning, may reduce the ERR of RIC when risk is predicted using a linear model. Observing the opposite effect, with a nonlinear model, however, questions the validity of these biologically parameterized models.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20800383     DOI: 10.1016/j.ijrobp.2010.05.035

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

Review 1.  The concept and evolution of involved site radiation therapy for lymphoma.

Authors:  Lena Specht; Joachim Yahalom
Journal:  Int J Clin Oncol       Date:  2015-07-07       Impact factor: 3.402

Review 2.  Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.

Authors:  Andrea Riccardo Filippi; Mario Levis; Rahul Parikh; Bradford Hoppe
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

Review 3.  Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma.

Authors:  Victor J Gonzalez
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

4.  Second Cancer Risk after simultaneous integrated boost radiation therapy of right sided breast cancer with and without flattening filter.

Authors:  Barbara Dobler; Johannes Maier; Bernadette Knott; Manuel Maerz; Rainer Loeschel; Oliver Koelbl
Journal:  Strahlenther Onkol       Date:  2016-08-17       Impact factor: 3.621

Review 5.  Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.

Authors:  David J Iberri; Richard T Hoppe; Ranjana H Advani
Journal:  Curr Treat Options Oncol       Date:  2015-09

Review 6.  Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?

Authors:  Frank Lohr; Dietmar Georg; Luca Cozzi; Hans Theodor Eich; Damien C Weber; Julia Koeck; Barbara Knäusl; Karin Dieckmann; Yasser Abo-Madyan; Christian Fiandra; Rolf-Peter Mueller; Andreas Engert; Umberto Ricardi
Journal:  Strahlenther Onkol       Date:  2014-09-11       Impact factor: 3.621

Review 7.  Evolution of the techniques of radiation therapy in the management of lymphoma.

Authors:  Richard T Hoppe
Journal:  Int J Clin Oncol       Date:  2013-04-11       Impact factor: 3.402

8.  Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer.

Authors:  E M Donovan; H James; M Bonora; J R Yarnold; P M Evans
Journal:  Med Phys       Date:  2012-10       Impact factor: 4.071

9.  Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy?

Authors:  Vitaliana De Sanctis; Chiara Bolzan; Marco D'Arienzo; Stefano Bracci; Alessandro Fanelli; Maria Christina Cox; Maurizio Valeriani; Mattia F Osti; Giuseppe Minniti; Laura Chiacchiararelli; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2012-08-02       Impact factor: 3.481

10.  Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease.

Authors:  Delphine Antoni; Shanti Natarajan-Ame; Philippe Meyer; Claudine Niederst; Khalil Bourahla; Georges Noel
Journal:  Radiat Oncol       Date:  2013-05-02       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.